Mariam Abdelnaby | Biology and Life Sciences | Innovative Research Award

 

Innovative Research Award

Mariam Abdelnaby
Moscow Institute for Physics and Technology, Russia
Mariam Abdelnaby
Affiliation Moscow Institute for Physics and Technology
Country Russia
Scopus ID 60758060000
Documents 1
Subject Area Biology and Life Sciences
Event International Forensic Scientist Awards
ORCID 0009-0004-1674-4300

Mariam Abdelnaby is affiliated with the Moscow Institute for Physics and Technology and has contributed to research within the field of Biology and Life Sciences. Her published work focuses on adeno-associated virus (AAV) vectors, regenerative medicine, and cellular reprogramming, emphasizing both the scientific opportunities and technical limitations associated with gene delivery technologies. This article summarizes her scholarly profile, research contributions, publication record, and the relevance of her work to the International Forensic Scientist Awards.[1]

Abstract

This academic profile presents an overview of Mariam Abdelnaby’s current scholarly contributions in Biology and Life Sciences. Her published work investigates the application of adeno-associated viral vectors in regenerative medicine and cellular reprogramming while discussing vector specificity, delivery efficiency, biosafety considerations, and translational challenges. The publication reflects interdisciplinary research relevant to molecular biology, regenerative therapies, and biomedical innovation.[1]

Keywords

  • AAV vectors
  • Regenerative medicine
  • Cellular reprogramming
  • Gene therapy
  • Biology and Life Sciences

Introduction

Modern regenerative medicine increasingly depends upon efficient gene delivery systems capable of achieving targeted cellular modification while maintaining safety and reproducibility. Adeno-associated virus vectors have emerged as one of the most promising platforms because of their favorable biological characteristics and expanding clinical applications. Research evaluating both their advantages and inherent limitations contributes to the continued advancement of precision medicine and therapeutic innovation.[1]

Research Profile

Mariam Abdelnaby is affiliated with the Moscow Institute for Physics and Technology. According to the supplied research information, her current Scopus profile includes one indexed scholarly publication. Citation count and h-index values were not available at the time of preparation and are therefore reported as unavailable pending future database updates.[1]

Research Contributions

  • Evaluation of AAV vector applications in regenerative medicine.
  • Discussion of cellular reprogramming methodologies.
  • Analysis of specificity constraints affecting gene delivery.
  • Assessment of potential translational and clinical limitations.
  • Contribution to interdisciplinary molecular biology literature.

Publications

  1. AAV Vectors in Regenerative Medicine and Cellular Reprogramming: Potential, Pitfalls, and Specificity Constraints. International Journal of Molecular Sciences, July 2026.

Research Impact

Although the available publication record currently consists of one indexed journal article, the research addresses an important and rapidly developing area of biomedical science. Topics including viral vector engineering, regenerative medicine, and cellular reprogramming continue to attract substantial international research interest because of their potential applications in disease treatment and precision therapeutics.[1]

Award Suitability

Based on the available scholarly information, Mariam Abdelnaby demonstrates active participation in contemporary biological and molecular research through peer-reviewed publication. Her work aligns with scientific themes involving advanced biotechnology, regenerative medicine, and molecular innovation, making it relevant for consideration within the International Forensic Scientist Awards. Any formal award evaluation should additionally consider independent peer review, scientific quality, originality, research influence, and verified bibliometric indicators.[1]

Conclusion

Mariam Abdelnaby’s available publication contributes to ongoing discussions surrounding regenerative medicine and AAV-mediated cellular engineering. While bibliometric indicators remain limited in the currently available profile, the published research reflects engagement with scientifically relevant challenges in modern molecular medicine. Future publications and citation development will provide additional evidence regarding long-term scholarly influence.[1]

External Links

References

  1. Abdelnaby M. AAV Vectors in Regenerative Medicine and Cellular Reprogramming: Potential, Pitfalls, and Specificity Constraints. International Journal of Molecular Sciences. 2026;27(15):6846.
    DOI: https://doi.org/10.3390/ijms27156846

Xiuqin Bao | Biology | Best Researcher Award

Dr. Xiuqin Bao | Biology | Best Researcher Award

Guangdong Women and Children Hospital | China

Dr. Xiuqin Bao is a dedicated Associate Research Fellow specializing in medical genetics, with a strong background in epigenetic regulation and prenatal diagnostics. Her work focuses on developing innovative genetic therapies, particularly for blood disorders like β-thalassemia. She has co-authored multiple high-impact publications and contributed to significant research grants.

Professional profile👤

ORCID

Strengths for the Awards✨

  • Strong Research Background:

    • Ph.D. in Genetics with a high GPA (3.8/4.0).

    • Focused research on β-thalassemia and γ-globin reactivation, a critical area in genetic medicine.

    • Published 8 papers, including multiple first/co-first author contributions in high-impact journals (IF 9.4–11.025).

  • Innovative Contributions:

    • Developed CRISPR-Cas9 editing strategies for HBG2 promoter activation.

    • Identified DNA methylation biomarkers for γ-globin reactivation.

    • Co-invented a ddPCR-based assay for α-globin gene CNV detection (patent holder).

  • Research Leadership & Funding:

    • Secured two major funded projects as Principal Investigator (total ¥350K).

    • Contributed to a ¥5.4M National Key R&D Program.

    • Recognized as Guangdong Outstanding Young Scholar (2024–2027).

  • Clinical & Technical Expertise:

    • Handles 500+ clinical cases annually with a 99% diagnostic accuracy.

    • Expertise in CRISPR, omics, and bioinformatics.

Education 🎓

Dr. Bao earned her Ph.D. and M.S. in Genetics from Southern Medical University (2015–2020), where she investigated the epigenetic regulation of γ-globin reactivation in β-thalassemia. She also holds a B.S. in Biopharmaceuticals (2011–2015) and was recognized with multiple academic excellence awards, including the First-Class Academic Scholarship.

Experience 💼

Currently serving as a Clinical Laboratory Technologist at Guangdong Women and Children Hospital, Dr. Bao conducts advanced prenatal diagnostic testing for thalassemia. She previously led epigenetic research projects as a Doctoral Researcher at Southern Medical University, contributing to groundbreaking discoveries in DNA methylation biomarkers and CRISPR-Cas9 editing for γ-globin activation.

Research Interests On Biology 🔬

Dr. Bao’s primary research focus is on the genetic and epigenetic mechanisms underlying hereditary blood disorders. She is particularly interested in using CRISPR gene-editing technology to reactivate fetal hemoglobin, offering potential therapeutic strategies for β-thalassemia. Her work also extends to biomarker discovery for precision medicine applications.

Awards 🏆

Dr. Bao has received several prestigious awards, including:

  • Guangdong Outstanding Young Scholar (2024–2027)
  • First-Class Academic Scholarships (2016, 2017, 2022)
  • Outstanding Communist Party Member (2018–2019) Her contributions to medical genetics have been recognized nationally and internationally.

Publications 📚

Dr. Bao has authored numerous high-impact publications, including:

  • “Activation of γ-globin expression by LncRNA-mediated ERF promoter hypermethylation in β-thalassemia”

    • Co-authors: Yuanyi Gao, Zhongju Wang, Yuhua Ye, Diyu Chen, Yangjin Zuo, Cunyou Zhao, Xiangmin Xu

    • Publication Year: 2024

  • “DNA methylation patterns of β-globin cluster in β-thalassemia patients”

    • Co-authors: Yangjin Zuo, Diyu Chen, Cunyou Zhao

    • Publication Year: 2020

    • Citations: 7

  • “Abnormal hemoglobin anti-Lepore Hong Kong compound with β⁰-thalassemia ameliorate thalassemia severity when co-inherited with α-thalassemia”

    • Co-authors: Jicheng Wang, Danqing Qin, Cuize Yao, Jie Liang, Kailing Liang, Li Du

    • Publication Year: 2024

  • “Severe fetal anemia and hydrops fetalis associated with compound heterozygosity for Hb Zurich-Albisrieden (HBA2:c.178G>C) and Hb Quong Sze (HBA2:c.377T>C)”

    • Co-authors: Li Du, Wei He, Danqing Qin, Jicheng Wang, Ying Xiong, Xiaomei Shi, Hongke Ding, Cuize Yao, Jing Wu

    • Publication Year: 2021

  • “Identification and characterization of CHD4-associated eRNA as a novel modulator of fetal hemoglobin levels in β-thalassemia”

    • Co-authors: Not specified

    • Publication Year: 2024

    • Citations: 1

  • “Two novel deletion mutations in β-globin gene cause β-thalassemia trait in two Chinese families”

    • Co-authors: Danqing Qin, Jicheng Wang, Jing Chen, Cuize Yao, Jie Liang, Kailing Liang, Yixia Wang, Yousheng Wang, Li Du, Aihua Yin

    • Publication Year: 2023

  • “Different effects of anxiety and avoidance dimensions of attachment on interpersonal trust: A multilevel meta-analysis”

    • Co-authors: Song Li, Yaoyao Zhang, Qingting Tang, Xu Chen

    • Publication Year: 2022

Conclusion 📝

Dr. Xiuqin Bao is a leading researcher in medical genetics, whose work in epigenetic modulation and gene therapy holds great promise for the future of hereditary blood disorder treatments. Through her extensive research, publications, and clinical expertise, she continues to contribute significantly to the advancement of genetic medicine.